Consider Steglatro as Another Flozin for Type 2 Diabetes
August 2018
Steglatro (steh-GLAH-troh, ertugliflozin) will be the fourth SGLT2 inhibitor for type 2 diabetes in Canada.
Steglatro will join the other "flozins"...Invokana (canagliflozin), Forxiga (dapagliflozin), and Jardiance (empagliflozin).
All flozins lower A1C by about 0.4% to 0.7% and help patients lose about 2 to 3 kg of weight. But it's too soon to say if Steglatro has the CV benefits seen with Jardiance or Invokana.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive